AstraZeneca-CICC Healthcare Venture Fund Closes Over RMB 2.2 Billion in Initial Funding and Files Prospectus

AstraZenecaAnnounced with CICC Capital that the first global healthcare industry fund of both parties, the "AstraZeneca CICC Healthcare Venture Capital Fund," has completed over RMB 2.2 billion in Phase I financing, and on January 28, 2021, in ChinaSecuritiesThe Asset Management Association of China has completed the filing for the private equity investment fund, which is a cross-SinopharmAstraZeneca co-launched a professional, market-oriented initiative with a major Chinese domestic financial institution for the first time.Medical Fund, will officially enter the target investment phase.

The participants of the fund include Wuxi High-tech Zone New Kinetic Energy Development Fund, Wuxi Guolian Development Group,Yuwell Medical、Tigermedincluding well-known industrial investors. Upon completion of the filing for the Phase I financing of the fund, subsequent fundraising activities, including those for the planned USD-denominated fund, will commence immediately. According to the plan, a significant portion of the capital in this global healthcare industry fund will be allocated to investments in China.Innovative Drugs, will also be used to invest in medical devices, diagnostics,Biotechnology, AI services, and other ecosystem businesses. While focusing primarily on growth-stage companies, the fund will also cover the entire industry chain, including global new drug R&D, production operations, and commercialization.